BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.
Joseph KauerMelanie MärklinMartin PflüglerSebastian HörnerClemens HinterleitnerClaudia TandlerGundram JungHelmut R SalihJonas S HeitmannPublished in: Journal of cancer research and clinical oncology (2022)
In conclusion, we propose that nilotinib and imatinib might also be suitable substances for combination with blinatumomab and suggest evaluation in clinical trials.